Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin in preclinical studies

03-Apr-2007

Pieris AG announced it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific Anticalin® with extended serum half life, were achieved in a tumor xenograft model, thereby supporting the development of a superior biotherapeutic for a range of cancer indications.

PRS-050 targets VEGF, a key positive regulator of angiogenesis important in several diseases including cancer and neovascular eye disorders. PRS-050 exhibits a favorable binding and functional in vitro activity profile in direct comparison to all currently approved VEGF antagonists. Strong reduction of VEGF-induced enhanced vascular permeability after systemic administration of PRS-050 was also demonstrated in a second preclinical model. In both in vivo models PRS-050 was at least as efficacious as Avastin® (bevacizumab; Genentech / Roche).

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance